Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the present work two second-order calibration methods, generalized rank annihilation method (GRAM) and multivariate curve resolution-alternating least square (MCR-ALS) have been applied on standard addition data matrices obtained by gas chromatography-mass spectrometry (GC-MS) to characterize and quantify four unsaturated fatty acids cis-
9-hexadecenoic acid
(C16:1omega7c), cis-9-octadecenoic acid (C18:1omega9c), cis-11-eicosenoic acid (C20:1omega9) and cis-13-docosenoic acid (C22:1omega9) in fish oil considering matrix interferences. With these methods, the area does not need to be directly measured and predictions are more accurate. Because of non-trilinear conditions of GC-MS data matrices, at first MCR-
ALS
and GRAM have been used on uncorrected data matrices. In comparison to MCR-
ALS
, biased and imprecise concentrations (%R.S.D.=27.3) were obtained using GRAM without correcting the retention time-shift. As trilinearity is the essential requirement for implementing GRAM, the data need to be corrected. Multivariate rank alignment objectively corrects the run-to-run retention time variations between sample GC-MS data matrix and a standard addition GC-MS data matrix. Then, two second-order algorithms have been compared with each other. The above algorithms provided similar mean predictions, pure concentrations and spectral profiles. The results validated using standard mass spectra of target compounds. In addition, some of the quantification results were compared with the concentration values obtained using the selected mass chromatograms. As in the case of strong peak-overlap and the matrix effect, the classical univariate method of determination of the area of the peaks of the analytes will fail, the "second-order advantage" has solved this problem successfully.
...
PMID:Second-order standard addition for deconvolution and quantification of fatty acids of fish oil using GC-MS. 1907 46
Growing evidence supports a link between fatty acid metabolism and
amyotrophic lateral sclerosis
(
ALS
). Here we determined the fatty acid composition of blood lipids to identify markers of disease progression and survival. We enrolled 117 patients from two clinical centers and 48 of these were age and gender matched with healthy volunteers. We extracted total lipids from serum and blood cells, and separated fatty acid methyl esters by gas chromatography. We measured circulating biochemical parameters indicative of the metabolic status. Association between fatty acid composition and clinical readouts was studied, including
ALS
functional rating scale-revised (ALSFRS-R), survival, disease duration, site of onset and body mass index.
Palmitoleate
(16:1) and oleate (18:1) levels, and stearoyl-CoA desaturase indices (16:1/16:0 and 18:1/18:0) significantly increased in blood cells from
ALS
patients compared to healthy controls.
Palmitoleate
levels and 16:1/16:0 ratio in blood cells, but not body mass index or leptin concentrations, negatively correlated with ALSFRS-R decline over a six-month period (p<0.05). Multivariate Cox analysis, with age, body mass index, site of onset and ALSFRS-R as covariables, showed that blood cell 16:1/16:0 ratio was an independent prognostic factor for survival (hazard ratio=0.1 per unit of ratio, 95% confidence interval=0.01-0.57, p=0.009). In patients with high 16:1/16:0 ratio, survival at blood collection was extended by 10 months, as compared to patients with low ratio. The 16:1/16:0 index is an easy-to-handle parameter that predicts survival of
ALS
patients independently of body mass index. It therefore deserves further validation in larger cohorts for being used to assess disease outcome and effects of disease-modifying drugs.
...
PMID:Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis. 2614 10